7th September 2026
Britain's decision to ban trade in goods produced in Israeli settlements in the occupied West Bank marks a significant new stage in the country's increasingly strained relationship with Israel but the more unexpected danger may lie across the Atlantic.
The Government's move, to be announced by Foreign Secretary Ed Miliband, is intended to put pressure on Israel over the expansion of settlements and particularly the proposed E1 development, which Britain believes could undermine the possibility of a viable Palestinian state. The United Kingdom, like most of the international community, regards Israeli settlements in the West Bank as illegal under international law, although Israel rejects that interpretation.
The immediate economic impact on Britain is unlikely to be dramatic. Israel is an important trading partner, but it is not one of Britain's largest. Official figures show that UK trade in goods and services with Israel amounted to about £6.2 billion in the four quarters to September 2025. British exports were approximately £3.7 billion and imports £2.5 billion. Israel accounted for only around 0.3 per cent of Britain's total trade.
Yet those figures conceal some strategically important relationships.
Israel has a much greater significance in certain sectors than the overall trade figures suggest, particularly pharmaceuticals, healthcare technology, science and biotechnology. Israeli pharmaceutical companies have a major presence in the NHS. Evidence presented to Parliament states that Israeli companies supply approximately one in seven NHS prescriptions, saving the health service nearly £3 billion a year.
That figure needs to be understood correctly. It does not mean Britain imports 25 per cent of all its medicines from Israel. Nor does it mean that one in seven medicines is necessarily manufactured inside Israel. Companies such as Teva are Israeli-owned multinationals with production and supply operations extending across several countries.
But the relationship is nevertheless substantial. NHS Scotland's own procurement records, for example, show numerous contracts with Teva UK covering generic medicines, cancer treatments, antibiotics, antivirals, fertility products, neurological and psychiatric medicines and other treatments.
That illustrates the difficulty of using trade sanctions in a modern global economy. A company can be Israeli-owned while manufacturing medicines somewhere else. A British subsidiary can supply the NHS while its parent company operates internationally. Determining precisely which activities should be restricted can therefore become considerably more complicated than simply putting a tariff on goods marked "Made in Israel".
The Government appears conscious of that distinction. Its policy is initially directed at goods produced in Israeli settlements, rather than a blanket boycott of Israeli products. Britain has already gone further in June by warning British citizens and businesses not to conduct economic and financial activities in illegal Israeli settlements.
The danger comes if the policy expands.
If Britain were eventually to restrict not only settlement-produced goods but also financial services, investment, insurance, technology, construction or companies with commercial connections to settlements, the economic consequences could become considerably greater.
And that is where America enters the story.
The United States has a network of federal and state laws designed to discourage companies and public bodies from participating in boycotts of Israel. Florida provides one of the clearest examples. Its 2026 legislation defines a boycott of Israel broadly enough to include refusing to deal with Israel or entities doing business in Israel or in Israeli-controlled territories in a discriminatory manner. Companies regarded as participating in such a boycott can face restrictions involving state investment and government contracts.
That has prompted warnings from American politicians that British companies complying with the new British policy could potentially find themselves exposed to American restrictions.
This is an important warning, but it must not be overstated. There is currently no evidence that the US government has imposed sanctions on Britain in response to the West Bank measures. The threat so far comes from American political figures and commentators rather than from an announced White House policy.
Nevertheless, the possibility raises an extraordinary legal problem.
Imagine a British company operating in London, New York and Israel. British law tells it not to conduct certain business connected with Israeli settlements. American law, depending upon the circumstances and the state involved, could potentially penalise the same company for participating in what is regarded as an anti-Israel boycott.
The company could find itself caught between two allied governments demanding different behaviour.
Florida's law is particularly significant because it can prevent companies participating in a boycott of Israel from obtaining certain state and local government contracts, while state investment funds can also be required to divest from companies placed on the relevant scrutiny list.
For a large multinational, that could be more serious than the value of the Israeli trade itself.
There is also the possibility of an Israeli response. Israeli Foreign Minister Gideon Sa'ar has warned that Israel would retaliate against countries taking punitive action, while Finance Minister Bezalel Smotrich has taken an even harder line. Calls for diplomatic retaliation, including against Britain's ambassador, have already emerged.
Britain therefore faces an unusual three-way balancing act.
It wants to put pressure on the Israeli government over settlement expansion. It wants to maintain its close strategic relationship with the United States. And it wants to protect British companies and institutions from becoming caught in an international legal dispute.
The Government's decision to act now reflects its belief that settlement expansion has reached a point at which diplomatic expressions of concern are no longer sufficient. But the economic weapon being used is potentially more complicated than it appears.
The £6.2 billion trading relationship with Israel is relatively small compared with Britain's overall economy. Yet particular companies can be extremely important. The pharmaceutical relationship with Israel demonstrates how a relatively modest bilateral trading relationship can contain strategically important supply chains.
The same principle applies to technology, medical research and defence-related cooperation.
The real test, therefore, will be the scope of the British measures.
If the Government confines them to clearly identified goods produced within settlements, the direct economic consequences are likely to be manageable. If it expands the policy to companies, services and financial relationships associated with settlements, the possibility of American retaliation becomes considerably more serious.
That is because the dispute would then stop being solely about Britain's relationship with Israel. It could become a dispute about whether British companies are legally required to behave in America in ways that American states regard as participation in an Israel boycott.
For the moment, that remains a possibility rather than an established American policy.
But the warning signs are there.
Britain may have calculated that it can draw a clear line between opposing Israeli settlement expansion and boycotting Israel itself. Washington's anti-boycott laws may make that distinction far less straightforward.
The irony is that Britain's new policy could therefore have consequences far beyond the West Bank.
What begins as an attempt to influence Israeli settlement policy could become a test of the increasingly complicated relationship between London, Jerusalem and Washington — and a test of how far an allied government can pursue an independent foreign policy when its companies operate within another country's legal system.
For British businesses, the question will be simple but uncomfortable: when British law and American law point in different directions, which one should a multinational company obey?
That may ultimately prove to be the most important consequence of Britain's new West Bank policy.